WebSep 1, 2024 · OnkoSight Advanced NGS testing provides targeted gene content that is aligned with the latest National Comprehensive Cancer Network (NCCN) and World Health Organization (WHO) guideline... WebGenPath employs specialized board-certified pathologists in the fields of gastroenterology, genitourinary, surgical pathology, hematopathology, dermatopathology, and cytology. Tests Offered By Laboratory Type GenPath can serve as …

GenPath Diagnostics Division of BioReference …

WebFeb 25, 2015 · The company will offer this next-generation sequencing program, called OnkoSight, through its GenPath Oncology business unit. The custom-designed NGS panels ar OnkoSight Solid, consisting of 31 genes for solid tumors; and OnkoSight Myeloid, comprising 37 genes for myeloid disorders. WebOnkoSight™ Advanced Lung Cancer NGS Report Final Report Patient Name: SAMPLE, PATIENT DOB: 01/02/1934 Specimen ID: XXXXXXXXX James Weisberger M.D. Laboratory Director GenPath is a business unit of BioReference Laboratories, Inc. Electronically signed by Wojciech Swat, PhD, FACMG 481 Edward H. Ross Drive Elmwood Park, NJ 07407 … cell phone battery slightly bulging

OnkoSight TM Next Generation Sequencing - GenPath

WebOnkoSight™ Advanced Lung Cancer NGS Report Final Report Patient Name: SAMPLE, PATIENT DOB: 01/02/1934 Specimen ID: XXXXXXXXX James Weisberger M.D. … WebOnkosight™ was developed and its performance characteristics were determined by GenPath, a division of BioReference Laboratories. This test has not been cleared or approved by the US Food and Drug Administration (FDA). The FDA has determined that such a clearance or approval is not necessary. Pursuant to the requirements of WebOnkoSight TM is GenPath’s proprietary product line of Next-Generation Sequencing (NGS) assays for hematologic malignancies and solid tumors that focuses on only actionable … Headquarters. 481 Edward H. Ross Dr. Elmwood Park, NJ 07407-0621 … cell phone battery stabbed